Ixekizumab–Tirzepatide Pair Moves Biomarkers in Psoriatic Obesity
Dermatology Times: ixekizumab plus tirzepatide shifted biomarkers in psoriasis patients with obesity. Detailed PASI, inflammatory, and metabolic endpoint data remain pending publication.